{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:41:12Z","timestamp":1788716472197,"version":"build-2803163510"},"reference-count":34,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,3,15]],"date-time":"2020-03-15T00:00:00Z","timestamp":1584230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunosuppressive therapies, effective in treating inflammatory disorders such as psoriasis, increase the risk of serious infections, such as tuberculosis (<jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content>). For example, tumour necrosis factor (<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>)\u2010alpha inhibitors significantly increase the risk of <jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content> reactivation in patients with latent TB infection (LTBI), which has led clinicians to routinely test for <jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content> prior to initiation of these medications. This protocol has since extended to other, newer immunomodulatory therapies for psoriasis, such as interleukin (<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>)\u201017 inhibitors, including secukinumab, ixekizumab and brodalumab. We conducted a systematic review to examine whether there is any evidence that <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017 inhibitor therapy for psoriasis increases the risk of <jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content> reactivation. Using PubMed and <jats:styled-content style=\"fixed-case\">EMBASE<\/jats:styled-content>, our literature search resulted in 139 total articles. After manually reviewing each article for the discussion of <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017 inhibitors for psoriasis, with data originating from clinical trials, and assessment for incidence of <jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content> reactivation, 23 articles met the full inclusion criteria for our review. Overall, we found no cases of <jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content> reactivation in patients treated with <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017 inhibitors for psoriasis. This suggests that <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017 inhibitors may be safely used in psoriasis patients with <jats:styled-content style=\"fixed-case\">LTBI<\/jats:styled-content> who receive appropriate <jats:styled-content style=\"fixed-case\">LTBI<\/jats:styled-content> treatment. However, long\u2010term real\u2010world studies are warranted to further evaluate this risk.<\/jats:p>","DOI":"10.1111\/jdv.16254","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T21:01:39Z","timestamp":1580763699000},"page":"1449-1456","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Risk of tuberculosis reactivation during interleukin\u201017 inhibitor therapy for psoriasis: a systematic review"],"prefix":"10.1111","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2731-1728","authenticated-orcid":false,"given":"E.","family":"Fowler","sequence":"first","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.I.","family":"Ghamrawi","sequence":"additional","affiliation":[{"name":"Edward Via College of Osteopathic Medicine Auburn AL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ghiam","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of California San Francisco San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-1892","authenticated-orcid":false,"given":"J.J.","family":"Wu","sequence":"additional","affiliation":[{"name":"Dermatology Research and Education Foundation Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,15]]},"reference":[{"key":"e_1_2_5_2_1","unstructured":"World Health Organization.Latent tuberculosis infection: Scaling up programmatic management of LTBI a critical action to achieve the WHO End TB Strategy targets[Internet] 2016. URLhttps:\/\/www.who.int\/tb\/challenges\/ltbi_factsheet_25nov15.pdf?ua=1(last accessed: 26 August 2019)."},{"key":"e_1_2_5_3_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D3249041425","article-title":"Tuberculosis and interleukin blocking monoclonal antibodies: is there risk?","volume":"24","author":"Kelsey A","year":"2018","journal-title":"Dermatol Online J"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1443198"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12628"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018607"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.0718"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.10.005"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.013"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2017.34"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.024"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1221923"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1882-2"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14878"},{"key":"e_1_2_5_15_1","first-page":"381","article-title":"Secukinumab demonstrates a consistent safety profile with up to 5\u00a0years treatment in patients with psoriatic arthritis and moderate to severe plaque psoriasis: updated pooled safety analyses","volume":"77","author":"Mease PJ","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key075.409"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez107.073"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-eular.3565"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.02.1043"},{"key":"e_1_2_5_20_1","first-page":"683","article-title":"Secukinumab demonstrates consistent safety over long\u2010term exposure in patients with psoriatic arthritis and moderate\u2010to\u2010severe plaque psoriasis: updated pooled safety analyses","volume":"76","author":"Mease P","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17604"},{"key":"e_1_2_5_22_1","first-page":"e51","article-title":"No reactivation of tuberculosis in Patients with latent tuberculosis infection while on ixekizumab treatment: a report from 11 clinical studies","volume":"28","author":"Suess S","year":"2019","journal-title":"Exp Dermatol"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15723"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.026"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key182"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2017.02.005"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15287"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.01.757"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.056"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0328-3"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022445"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.03.023"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.16254","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16254","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.16254","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T18:31:47Z","timestamp":1693938707000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.16254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,15]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1111\/jdv.16254"],"URL":"https:\/\/doi.org\/10.1111\/jdv.16254","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,15]]},"assertion":[{"value":"2019-11-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}